R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.

BioMarin leads R&D spending, Catalyst shows growth.

__timestampBioMarin Pharmaceutical Inc.Catalyst Pharmaceuticals, Inc.
Wednesday, January 1, 201446154300010117774
Thursday, January 1, 201563480600011801342
Friday, January 1, 201666190500011369941
Sunday, January 1, 201761075300011375237
Monday, January 1, 201869632800019919204
Tuesday, January 1, 201971500700018842752
Wednesday, January 1, 202062811600016496715
Friday, January 1, 202162879300016936000
Saturday, January 1, 202264960600019789000
Sunday, January 1, 202374677300093150000
Loading chart...

Igniting the spark of knowledge

The R&D Race: BioMarin vs. Catalyst Pharmaceuticals

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, BioMarin Pharmaceutical Inc. has consistently outpaced Catalyst Pharmaceuticals, Inc. in R&D investment. From 2014 to 2023, BioMarin's R&D expenses surged by approximately 62%, peaking at $747 million in 2023. In contrast, Catalyst Pharmaceuticals saw a more modest increase, with R&D spending reaching $93 million in 2023, a significant jump from previous years but still a fraction of BioMarin's budget.

This disparity highlights BioMarin's aggressive pursuit of new treatments and therapies, positioning it as a leader in the biotech sector. Meanwhile, Catalyst's recent uptick in spending suggests a strategic shift towards innovation. As these companies continue to invest in R&D, the pharmaceutical landscape is poised for exciting developments.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025